Key Takeaways

  • ViaLase has completed the first commercial FLIGHT glaucoma procedures in Europe using its incision-free ViaLuxe Laser System 
  • The procedures were performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD
  • The FLIGHT procedure uses image-guided femtosecond laser technology and high-resolution OCT imaging to create precise channels through the trabecular meshwork

ViaLase announced the completion of the first commercial FLIGHT procedures in Europe. The procedures were performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD.

The FLIGHT procedure was performed using the ViaLuxe Laser System, an incision-free, image-guided femtosecond laser platform designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce IOP in patients with open-angle glaucoma.

“Centre for Sight has always been committed to bringing meaningful innovation to patients through technologies that advance precision, safety, and the overall treatment experience,” said Dr. Daya, Medical Director and Founder of Centre for Sight. “We are proud to be the first center globally to introduce the FLIGHT procedure, marking a redefinition of glaucoma care.”

“There remains a significant need for incision-free glaucoma treatment options that can be introduced earlier in the disease continuum,” Dr. Klabe said. “It is a privilege to be the first centre in Germany to bring the FLIGHT procedure into clinical practice.”

The ViaLuxe Laser System combines high-resolution optical coherence tomography (OCT) imaging with proprietary femtosecond laser technology to enable image-guided treatment delivery with micron-level precision.

“This marks an important milestone for ViaLase as we begin the commercial introduction of FLIGHT globally,” said Pete England, Chief Commercial Officer at ViaLase. “We believe this treatment has the potential to advance interventional glaucoma by enabling earlier, safer intervention to help patients reach target pressures and slow disease progression. ViaLase is proud to partner with globally respected thought leaders as we bring this technology into clinical practice.”

The company said it is supporting its initial European launch through a targeted network of distributor partners in select markets, including an exclusive distribution agreement with Carleton Optical in the United Kingdom.

The surgery marked the first commercial FLIGHT procedure in Europe. The technology received CE Mark in 2024. In the US, ViaLase is conducting a pivotal IDE trial structured to support future regulatory clearance and commercialization.